LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-driven Antibody Optimisation Programmes

About LabGenius Therapeutics This collaboration combines LabGenius' AI/ML-driven antibody design capabilities with Sanofi's expertise in the development of therapeutic NANOBODY® molecules to co- optimise proteins for therapeutically valuable properties LabGenius Therapeutics is a drug discovery company pioneering the discovery of next-generation therapeutic antibodies. The company's discovery platform, EVAâ"¢, integrates several cutting-edge technologies drawn from the fields of artificial intelligence, rob ...